These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18154212)

  • 21. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
    Reimer G; Brudler O; Heinrich B; Bangerter M
    MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
    Garden BC; Wu S; Lacouture ME
    J Am Acad Dermatol; 2012 Sep; 67(3):400-8. PubMed ID: 22088429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
    Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
    Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical research of EGFR inhibitors and related dermatologic toxicities.
    Perez-Soler R; Van Cutsem E
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
    Iacovelli L
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.
    Yamazaki N; Muro K
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):27-8. PubMed ID: 18159648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
    Santiago F; Gonçalo M; Reis JP; Figueiredo A
    An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
    Dasanu CA; Alvarez-Argote J; Lippman SM; Plaxe SC
    J Oncol Pharm Pract; 2018 Apr; 24(3):229-231. PubMed ID: 28436313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
    Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical management of cutaneous toxicity of anti-EGFR agents.
    Monti M; Motta S
    Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-targeted therapy and related skin toxicity.
    Morse L; Calarese P
    Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Cetuximab therapy and symptomatic hypomagnesemia.
    Altundag K; Altundag O; Baptista MZ; Turen S; Atik MA
    J Natl Cancer Inst; 2005 Dec; 97(23):1791-2. PubMed ID: 16333039
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting the epidermal growth factor receptor in colorectal carcinoma.
    Kurtin SE
    Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.